M/S I.e. Medica Inc., Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: M/S I.e. Medica Inc., Pharmaceutical Import Records from India — 3 Products, $5.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/S I.e. Medica Inc., — Pharmaceutical Importer Profile (2026) | 3 Products, $5.1M Trade | TransData Nexus

M/S I.e. Medica Inc.,

Pharmaceutical Importer · Philippines · Respiratory Focus · $5.1M Total Trade · DGFT Verified

M/S I.e. Medica Inc., is a pharmaceutical importer based in Philippines with a total trade value of $5.1M across 3 products in 1 therapeutic categories. Based on 128 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/S I.e. Medica Inc., sources from 1 verified Indian supplier, with Ahlcon Parenterals (india) Limited accounting for 100.0% of imports.

M/S I.e. Medica Inc., — Import Portfolio & Supplier Network

M/S I.e. Medica Inc., import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/S I.e. Medica Inc.,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ahlcon Parenterals (india) Limited	$1.7M	71	100.0%

M/S I.e. Medica Inc., sources from 1 verified Indian supplier across 31 distinct formulations. The sourcing is highly concentrated — Ahlcon Parenterals (india) Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Salbutamol & ipratropium bromide respirator solution 2.5ML (pulmodual)	$293.1K	8
Salbutamol nebuliser solution BP (2.5MG/2.5ML) (asmacaire)	$226.4K	6
Salbutamol nebuliser solution BP 2.5 ML(asmacaire)	$107.4K	4
Buedsonide nebuliser suspension BP (250mcg/2ML) (breecort) (Pack of 35) Each mlcontains budesonide BP 250mcg	$100.0K	2
Salbutamol nebuliser solution BP(2.5MG/2.5ML)(asmacaire)(Pack of 35)Each vial of2.5ML contains salbutamol sulphate 2.5MG	$100.0K	2
Salbutamol & ipratropium bromide respirator solution (pulmodual) 2.5 ML(Each 2.5ML vial contain salbutamol sulfate	$100.0K	2
Salbutamol nebuliser solution BP (2.5MG/2.5ML) (asmacaire) (Each vial of 2.5 mlvial contains salbutamol sulphate BP eq)	$100.0K	2
Salbutamol nebuliser solution BP (2.5MG/2.5ML)	$89.0K	5
Salbutamol nebuliser solution BP 1MG/ML(2.5MG/2.5ML)(ventar)(Each ML contain salbutamol sulfate BP eq to salbutamol 1MG	$64.6K	2
Salbutamol & ipratropium bromide respirator solution 2.5ML(Each vial of 2.5 ML contain salbutamol sulphate BP eq to sa )	$60.2K	2
Salbutamol nebuliser solution BP 2.5MG/2.5 ML (provexel ns)	$50.5K	3
Budesonide nebuliser suspension BP (breecort) 250mcg/ML (500mcg/2ML) (breecort)(tax invocie no. 9610045205	$50.0K	1
Budesonide nebuliser suspension BP (breecort) 250mcg/ML (500mcg/2ML) (breecort)	$50.0K	1
Salbutamol & ipratropium bromide respirator solution 2.5 ML (salresp-i)(Each vial of 2.5 ML contain salbutamol sulphate)	$50.0K	1
Salbutamol nebuliser solution BP (2.5MG/2.5ML)(Each vial of 2.5 ML vial containsalbutamol sulphate BP eq to salbutamol)	$43.6K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Salbutamol	Respiratory	$3.3M	86	1.3%	10
2	Ipratropium	Respiratory	$1.5M	36	1.3%	5
3	Budesonide	Respiratory	$300.0K	6	0.2%	16

M/S I.e. Medica Inc., imports 3 pharmaceutical products across 1 categories into Philippines totaling $5.1M.

M/S I.e. Medica Inc., — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

I.E. Medica, Inc. is a Philippine-based pharmaceutical company established in 2007, specializing in the global sourcing, importation, registration, and distribution of high-quality pharmaceutical products across various therapeutic areas. The company is headquartered at 5/F RFM Corporate Center, Pioneer Street, Mandaluyong City, Philippines. I.E. Medica's mission is to enhance healthcare accessibility and affordability for Filipinos by providing a wide range of quality medicines. (iemedica.com.ph)

In 2019, I.E. Medica formed a strategic partnership with Ayala Healthcare Holdings, Inc. (AC Health), the healthcare arm of Ayala Corporation, to strengthen its supply chain capabilities and expand its pharmaceutical portfolio. (iemedica.com.ph) This collaboration has enabled I.E. Medica to better serve the Philippine market by improving access to quality healthcare products. (mb.com.ph)

2Distribution Network

I.E. Medica's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the Philippines. The company operates warehouses located in Metro Manila, facilitating rapid distribution to various regions. In October 2024, I.E. Medica commenced construction of a new warehouse in the Cavite Technopark, aiming to enhance its supply chain efficiency and support future growth. (mb.com.ph) This facility is expected to be operational by 2026, further strengthening the company's logistics capabilities.

3Industry Role

I.E. Medica serves as a pharmaceutical importer and distributor in the Philippines, playing a crucial role in the country's healthcare supply chain. The company specializes in sourcing, importing, registering, and supplying a diverse range of pharmaceutical products, including generic medicines and innovative drug delivery systems. (iemedica.com.ph) By partnering with reputable manufacturers that comply with current Good Manufacturing Practices (cGMP) and international standards, I.E. Medica ensures the availability of quality medicines to meet the evolving needs of the Philippine market. (iemedica.com.ph)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/S I.e. Medica Inc.,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

I.E. Medica's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, AHLCON PARENTERALS (INDIA) LIMITED. This supplier has been responsible for 100% of the company's shipments, amounting to $1.7 million across 71 shipments. Such a concentrated sourcing approach can present risks, including potential supply chain disruptions if the primary supplier faces operational challenges. However, it also indicates a strategic choice to maintain a consistent supply of specific products, ensuring quality and reliability. The stability of this relationship is crucial for I.E. Medica's operations, and any changes in the supplier's performance could significantly impact the company's ability to meet market demand.

2Supply Chain Resilience

I.E. Medica's supply chain resilience is closely tied to its reliance on a single supplier for a substantial portion of its pharmaceutical imports. The company's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, imported from India, suggests a streamlined supply chain with specific supplier dependencies. While this approach can lead to operational efficiencies, it also exposes the company to risks associated with supplier disruptions. The lack of backup suppliers and limited formulation diversity may challenge I.E. Medica's ability to adapt to unforeseen supply chain issues. Ensuring regulatory compliance of key suppliers and diversifying the supplier base could enhance the company's supply chain resilience.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation, registration, and distribution of pharmaceutical products. The FDA enforces regulations to ensure the safety, efficacy, and quality of medicines available in the market. Key legislation governing pharmaceutical imports includes the Food and Drug Administration Act of 2009 (Republic Act No. 9711), which provides the legal framework for the FDA's operations and responsibilities. The marketing authorization pathway for Indian generics involves obtaining a Certificate of Product Registration (CPR) from the FDA, ensuring that imported medicines meet the required standards for public use. (fda.gov.ph)

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that pharmaceutical products, including finished formulations, must be registered with the FDA before importation. Manufacturers, traders, and distributors with valid License to Operate (LTO) are authorized to import drug products and raw materials. Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the US-FDA, UK-MHRA, WHO-GMP, and PIC/S, are essential for ensuring product quality and are recognized by the Philippine FDA. Wholesale distribution authorization is granted to entities that comply with FDA regulations, ensuring that imported pharmaceutical products are distributed safely and effectively within the country. (fda.gov.ph)

M/S I.e. Medica Inc., — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

I.E. Medica's product strategy focuses on importing finished pharmaceutical formulations, such as Salbutamol, Ipratropium, and Budesonide, all within the respiratory therapeutic category. This focus aligns with the company's commitment to providing essential medicines that address prevalent health conditions in the Philippines. The market demand for respiratory medications is driven by factors such as the high incidence of respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), among the Filipino population. By concentrating on this therapeutic area, I.E. Medica aims to meet the critical healthcare needs of its target market.

2Sourcing Profile

I.E. Medica's sourcing strategy emphasizes the importation of generic drug formulations from India, particularly in the respiratory therapeutic category. The company's preference for finished pharmaceutical formulations indicates a focus on ready-to-market products that can be swiftly distributed to meet local demand. India's established pharmaceutical manufacturing industry, known for its adherence to international quality standards, aligns with I.E. Medica's commitment to providing high-quality medicines. This sourcing approach enables the company to offer affordable and accessible healthcare solutions to the Filipino market.

3Market Positioning

Seller's Guide — How to Become a Supplier to M/S I.e. Medica Inc.,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with I.E. Medica, especially those offering high-quality generic formulations in the respiratory therapeutic area. I.E. Medica's concentrated sourcing pattern suggests a potential openness to diversifying its supplier base, provided that new suppliers can meet the company's stringent quality standards and regulatory requirements. Identifying gaps in I.E. Medica's current sourcing, such as unmet product needs or opportunities for innovation, could further enhance the attractiveness of new suppliers.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to I.E. Medica and the Philippine market must obtain a Certificate of Product Registration (CPR) from the Philippine FDA. This process involves submitting documentary requirements, including Certificates of Analysis, proforma invoices, and packing lists, through the

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — M/S I.e. Medica Inc.,

What products does M/S I.e. Medica Inc., import from India?

M/S I.e. Medica Inc., imports 3 pharmaceutical products across 1 categories. Top imports: Salbutamol ($3.3M), Ipratropium ($1.5M), Budesonide ($300.0K).

Who supplies pharmaceuticals to M/S I.e. Medica Inc., from India?

M/S I.e. Medica Inc., sources from 1 verified Indian suppliers. The primary supplier is Ahlcon Parenterals (india) Limited (100.0% of imports, $1.7M).

What is M/S I.e. Medica Inc.,'s total pharmaceutical import value?

M/S I.e. Medica Inc.,'s total pharmaceutical import value from India is $5.1M, based on 128 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/S I.e. Medica Inc., focus on?

M/S I.e. Medica Inc., imports across 1 categories. The largest: Respiratory (100.0%).

Get Full M/S I.e. Medica Inc., Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.